WVP
TTPH

Worth Venture Partners’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Worth Venture Partners’s Portfolio TTPH Stock Details TTPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,466
Closed -$209K – 156
2017
Q2 		$209K Buy
+1,466
New +$227K 0.18% 84

Other funds holding TTPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Worth Venture Partners's TTPH Position: Q3 2017 in Review

Worth Venture Partners sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q3 2017, closing a stake of 1,466 shares — an estimated $209K sold.

Worth Venture Partners first reported a position in TTPH in Q2 2017 and held it in 1 quarter. The position peaked at $209K in Q2 2017. 94 funds tracked by Wall St. Rank hold TTPH as of Q3 2017.

  • Worth Venture Partners reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • Worth Venture Partners sold 1,466 Tetraphase Pharmaceuticals, Inc. shares in Q3 2017, an estimated $209K.
  • Worth Venture Partners first reported a position in Tetraphase Pharmaceuticals, Inc. in Q2 2017 and held it in 1 quarter.
  • Worth Venture Partners's Tetraphase Pharmaceuticals, Inc. position peaked at $209K in Q2 2017.
  • 94 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q3 2017.

Based on Worth Venture Partners's 13F filing for Q3 2017, filed 7 Nov 2017.